Diatos SA · Paris France
Company Description
Phone: +33-1-53-80-93-40
Fax: +33-1-53-80-93-89
View Diatos SA Locations On A US Map
This link will open in a new window
This link will open in a new window Diatos wants to say "adios" to the Big C. The private biopharmaceutical company develops therapies for cancer and other diseases with the help of its two key product lines: Diatos Peptide Vector (DPV) is a technology leveraging intra-cellular and intra-nuclear delivery, while its Tumor-Selective Prodrug (TSP) technology uses anti-cancer compounds for utilizing cancer targeting. Established in 1999, Diatos' business strategy involves developing and marketing new anti-cancer therapies that feature its peptide-based technologies and to also partner with other pharmaceutical and biotech businesses. With its chief office in France, Diatos also owns laboratories in Belgium and the US (San Francisco). To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Key Diatos SA Financials
| Company Type | |
| 2004 Employees | 44 |
Diatos SA Executives
8 executives listed for Diatos SA's Paris, location.
| Title | Name & Bio | Contact |
| President and CEO | John Tchelingerian | Network |
| Chief Medical Officer and Head Clinical Development and Regulatory Affairs | Jamal Gasmi | Network |
| General Counsel and Chief Legal Officer | Yann Christin | Network |
Competition
Competitive Landscape for Diatos SA
Demand is driven by population demographics and advances in medical knowledge and technology. The profitability of individual companies depends on the ability to develop superior products. Large companies have economies of scale in manufacturing and R&D. Small companies can compete successfully by specializing in a particular market segment, or through technical innovation. To read the full description, subscribe now.Top Diatos SA Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!